SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- SOTERIA Precision Medicine Foundation, a non-profit 501(c)(3) organization, announced a collaboration with Tempus (NASDAQ:TEM) to deliver personalized, data-driven cancer
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended September 30, 2026.
"Q3 was another record
Tempus AI, Inc. (NASDAQ:TEM) today announced that its xR assay has received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic device. The certification
Tempus AI, Inc. (NASDAQ:TEM, "Tempus")) today announced a multi-year agreement with Bristol Myers Squibb (NYSE:BMY, "BMS")), under which BMS will license multimodal oncology data from Tempus through 2031
Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreement
Pathos’s AI expertise and agentic
Study to be presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images
Tempus AI, Inc. (NASDAQ:TEM) today
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the third quarter ended September 30, 2026, before U.S.
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is starting to change the way healthcare works, and the opportunity is getting harder to ignore. From spotting diseases earlier to helping doctors
New offering combines whole genome sequencing, RNA analysis and ongoing reanalysis to help address diagnostic challenges
Ambry Genetics, a leader in clinical genomic testing and a wholly owned subsidiary of Tempus
Collaboration to Support Potential Commercialization of Intismeran Autogene
Tempus (NASDAQ:TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene
Equity Insider News Commentary AUSTIN, Texas, Oct. 1, 2026 /CNW/ -- Towards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound
Tempus AI, Inc. (NASDAQ:TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid.
At this
ECG-MR becomes the fourth FDA-cleared Tempus ECG-AI product, spanning arrhythmia, heart function, pulmonary vascular and valvular disease
Tempus AI, Inc. (NASDAQ:TEM) today announced it has received 510(k) clearance
Tempus AI, Inc. (NASDAQ:TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). Additionally, the two companies have entered into a new agreement under which
AUSTIN, Texas, Sept. 14, 2026 /CNW/ -- USA News Group News Commentary - Artificial intelligence is moving from the edges of drug discovery toward its center, and the market built around it is expanding quickly. Grand
